Skip to main content

Advertisement

SpringerLink
Log in

High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory–thrombotic processes

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

The exact prevalence and pathogenic role of antiphospholipid antibodies (aPL) in multiple sclerosis (MS) remain unclear. This observational laboratory-blinded study evaluated the rate of aPL positivity in healthy controls and MS patients in different disease phases to recognize their frequency and possible pathogenic meaning. Reactivity for anti-cardiolipin, anti-β2 glycoprotein I, anti-prothrombin, anti-annexin V (IgG and IgM) was studied by enzyme immunoassays in 60 healthy controls and 100 consecutive MS patients [58 relapsing–remitting (RR) patients in remission, 26 RR patients in relapse, and 16 secondary progressive patients]. The overall rate of positivity for at least one aPL was significantly higher in MS patients compared to controls (32 % vs. 7 %, respectively, p < 0.0001), and in relapsing phase compared to those remitting or secondary progressive (53.8, 20.7 and 37.5 %, respectively, p = 0.002). In the single aPL analysis, the rate of positivity was significantly higher in MS patients compared to controls for anti-prothrombin IgM (7 % vs. 0, p = 0.05), and in relapsing phase compared to remitting and secondary progressive phases for anti-β2 glycoprotein I IgM (26.9, 1.7, 6.3 %, respectively, p < 0.0001), anti-prothrombin IgM (15.4, 3.4, 6.3 %, respectively, p = 0.05) and IgG (19.2, 5.2, 0 %, respectively, p = 0.05). We showed a significant aPL increase in MS patients compared to healthy controls, particularly during disease relapse which was also associated with significantly higher values of anti-β2 glycoprotein I and anti-prothrombin. These data suggest that antiphospholipid antibody occurrence in multiple sclerosis could be related to modification of structure and function of proteins involved in the inflammatory–thrombotic processes during disease re-activation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lassmann H, Brück W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17:210–218

    Article  PubMed  Google Scholar 

  2. Ferreira S, D’Cruz DP, Hughes GR (2005) Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology 44:434–442

    Article  CAS  PubMed  Google Scholar 

  3. Cuadrado MJ, Khamashta MA, Ballesteros A et al (2000) Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine 79:57–68

    Article  CAS  PubMed  Google Scholar 

  4. Karussis D, Leker RR, Ashkenazi A, Abramsky O (1998) A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol 44:629–634

    Article  CAS  PubMed  Google Scholar 

  5. Spadaro M, Amendolea MA, Mazzucconi MG et al (1999) Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler 5:121–125

    Article  CAS  PubMed  Google Scholar 

  6. Roussel V, Yi F, Jauberteau MO et al (2000) Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun 14:259–265

    Article  CAS  PubMed  Google Scholar 

  7. Sastre-Garriga J, Reverter JC, Font J et al (2001) Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Ann Neurol 49:408–411

    Article  CAS  PubMed  Google Scholar 

  8. Heinzlef O, Weill B, Johanet C et al (2002) Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. J Neurol Neurosurg Psychiatry 72:647–649

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Bidot CJ, Horstman LL, Jy W et al (2007) Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol 7:36

    Article  PubMed Central  PubMed  Google Scholar 

  10. Garg N, Zivadinov R, Ramanathan M et al (2007) Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol 187:159–165

    Article  CAS  PubMed  Google Scholar 

  11. Szmyrka-Kaczmarek M, Pokryszko-Dragan A, Pawlik B et al (2012) Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus 21:412–420

    Article  CAS  PubMed  Google Scholar 

  12. McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127

    Article  CAS  PubMed  Google Scholar 

  13. Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306

    Article  CAS  PubMed  Google Scholar 

  14. Thompson AJ, Kermode AG, Wicks D et al (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29:53–62

    Article  CAS  PubMed  Google Scholar 

  15. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452

    Article  CAS  PubMed  Google Scholar 

  16. Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV (2012) The evidence for a role of B cells in multiple sclerosis. Neurology 78(11):823–832. doi:10.1212/WNL.0b013e318249f6f0.Review

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Colosimo C, Pozzilli C, Frontoni M et al (1997) No increase of serum autoantibodies during therapy with recombinant human interferon-beta1a in relapsing-remitting multiple sclerosis. Acta Neurol Scand 96(6):372–374

    Article  CAS  PubMed  Google Scholar 

  18. Speciale L, Saresella M, Caputo D et al (2000) Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b. J Neurovirol 6(Suppl 2):S57–S61

    CAS  PubMed  Google Scholar 

  19. Zivadinov R, Ramanathan M, Ambrus J et al (2012) Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurol Res 34:761–769

    Article  CAS  PubMed  Google Scholar 

  20. Giannakopoulos B, Krilis SA (2013) The pathogenesis of the antiphospholipid syndrome. N Engl J Med 368:1033–1044

    Article  CAS  PubMed  Google Scholar 

  21. Schwartz M, Kipnis J (2002) Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity: a paradigm shift. Neuroscientist 8:405–413

    Article  CAS  PubMed  Google Scholar 

  22. Esmon CT, Xu J, Lupu F (2011) Innate immunity and coagulation. J Thromb Haemost 9:182–188

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Loizou S, Singh S, Wypkema E, Asherson RA (2003) Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis 62(11):1106–1111

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Zinger H, Sherer Y, Goddard G et al (2009) Common infectious agents prevalence in antiphospholipid syndrome. Lupus 18:1149–1153

    Article  CAS  PubMed  Google Scholar 

  25. Mechelli R, Umeton R, Policano C et al (2013) A “candidate-interactome” aggregate analysis of genome-wide association data in multiple sclerosis. PLoS One 8:e63300

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Ben-Chetrit E, Wiener-Well Y, Fadeela A, Wolf DG (2013) Antiphospholipid antibodies during infectious mononucleosis and their long term clinical significance. J Clin Virol 56(4):312–315

    Article  CAS  PubMed  Google Scholar 

  27. Fiorini A, Koudriavtseva T, Bucaj E et al (2013) Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS One 8:e65184

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology Unit, Multiple Sclerosis Center, Regina Elena National Cancer Institute, IFO, Via Elio Chianesi 53, 00144, Rome, Italy

    Tatiana Koudriavtseva

  2. Clinical Pathology, San Gallicano Dermatology Institute, IFO, Rome, Italy

    Giovanna D’Agosto & Paola Cordiali-Fei

  3. Clinical Pathology, Regina Elena National Cancer Institute, IFO, Rome, Italy

    Chiara Mandoj

  4. Biostatistic Unit, Scientific Direction, Regina Elena National Cancer Institute, IFO, Rome, Italy

    Isabella Sperduti

Authors
  1. Tatiana Koudriavtseva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanna D’Agosto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiara Mandoj
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isabella Sperduti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paola Cordiali-Fei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tatiana Koudriavtseva.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koudriavtseva, T., D’Agosto, G., Mandoj, C. et al. High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory–thrombotic processes. Neurol Sci 35, 1737–1741 (2014). https://doi.org/10.1007/s10072-014-1823-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-014-1823-4

Keywords

Search

Navigation